From: Malignant hyperthermia when dantrolene is not readily available
 | Survived | Death |
---|---|---|
total outcome between 1985 and 2010 (n = 61) | 28 (45.9%) | 33 (54.1%) |
total outcome between 2011 and 2019 (n = 31) | 22 (71.0%) | 9 (29.0%) |
outcome between 1985 and 2010 without dantrolene (n = 59) | 26 (44.1%) | 33 (55.9%) |
outcome between 2011 and 2019 without dantrolene (n = 25) | 16 (64.0%) | 9 (36.0%) |